Etrasimod

A drug candidate for the treatment of immune-mediated and inflammatory diseases. Etrasimod is an investigational, once-daily, oral, selective S1P receptor modulator designed to partially and reversibly reduce lymphocyte levels at sites of inflammation, while maintaining components of immune function.

CLINICAL TRIALS

RISE UP AGAINST ULCERATIVE COLITIS (UC)
A worldwide, Phase 3 clinical program evaluating etrasimod—an oral, selective, sphingosine 1 phosphate (S1P) receptor modulator—for the treatment of moderately to severely active ulcerative colitis.

ClinicalTrials.gov: NCT03945188, NCT03996369, NCT03950232
ADDRESSING THE ROOT OF CROHN’S DISEASE (CD)
CULTIVATE is a Phase 2/3 clinical trial evaluating the efficacy and safety of once-daily, oral etrasimod in patients with moderately to severely active Crohn’s disease (CD).

ClinicalTrials.gov: NCT04173273 Patient Trial Site
BRINGING THE FIGHT TO UC
A Phase 2, 52-week induction and maintenance study evaluating the safety and efficacy of once-daily, oral etrasimod in patients with moderately active UC. Patients with disease activity insufficient to qualify for the ELEVATE program may be eligible to participate in GLADIATOR.

ClinicalTrials.gov: NCT04607837
Navigating a path forward in EoE
Phase 2 clinical trial evaluating the safety and efficacy of etrasimod in patients with eosinophilic esophagitis (EoE).

ClinicalTrials.gov: NCT04682639 Patient Trial Site

Clinical Trials

ULCERATIVE COLITIS

UC 52

Phase 3

UC 12

Phase 3

Phase 2

CROHN’S DISEASE

Phase 2/3

EOSINOPHILIC ESOPHAGITIS

Phase 2

ATOPIC DERMATITIS

Phase 3 Planning

ALOPECIA AREATA

Phase 2

Etrasimod is an investigational drug and is not currently approved for use by any health authority.
Retained Rights: Worldwide, excluding rights granted to Everest Medicines for Greater China and certain other Asian territories.